These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22235146)

  • 1. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
    Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
    J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
    Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
    Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
    Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
    Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
    Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
    Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
    Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
    Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P; Galán-Malo P; Marzo I; Naval J
    Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
    Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
    Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
    Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.
    Ao L; Wu Y; Kim D; Jang ER; Kim K; Lee DM; Kim KB; Lee W
    Mol Pharm; 2012 Aug; 9(8):2197-205. PubMed ID: 22734651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.
    Huber EM; Heinemeyer W; Groll M
    Structure; 2015 Feb; 23(2):407-17. PubMed ID: 25599643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib.
    Politou M; Karadimitris A; Terpos E; Kotsianidis I; Apperley JF; Rahemtulla A
    Leuk Res; 2006 Feb; 30(2):240-1. PubMed ID: 16081156
    [No Abstract]   [Full Text] [Related]  

  • 19. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
    Zang Y; Kirk CJ; Johnson DE
    Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.
    Oerlemans R; Berkers CR; Assaraf YG; Scheffer GL; Peters GJ; Verbrugge SE; Cloos J; Slootstra J; Meloen RH; Shoemaker RH; Dijkmans BAC; Scheper RJ; Ovaa H; Jansen G
    Invest New Drugs; 2018 Oct; 36(5):797-809. PubMed ID: 29442210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.